|Publication number||US5858326 A|
|Application number||US 08/471,093|
|Publication date||Jan 12, 1999|
|Filing date||Jun 6, 1995|
|Priority date||Jun 6, 1995|
|Also published as||CA2219447A1, WO1996039129A1|
|Publication number||08471093, 471093, US 5858326 A, US 5858326A, US-A-5858326, US5858326 A, US5858326A|
|Inventors||Robert Kisilevsky, Walter Szarek, Donald Weaver, Paul Fraser, Xianqi Kong|
|Original Assignee||Neurochem, Inc., Queen's University At Kingston|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (8), Non-Patent Citations (37), Referenced by (76), Classifications (25), Legal Events (9)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Amyloidosis refers to a pathological condition characterized by the presence of amyloid. Amyloid is a generic term referring to a group of diverse but specific extracellular protein deposits which are seen in a number of different diseases. Though diverse in their occurrence, all amyloid deposits have common morphologic properties, stain with specific dyes (e.g., Congo red), and have a characteristic red-green birefringent appearance in polarized light after staining. They also share common ultrastructural features and common x-ray diffraction and infrared spectra.
Amyloid can be classified according to the protein type, as described in a recent report (Kazatchkine et al., (1993) Bull. WHO 71:105). Different amyloidoses are also characterized by the type of protein present in the deposit. For example, neurodegenerative diseases such as scrapie, bovine spongiform encephalitis, Creutzfeldt-Jakob disease and the like are characterized by the appearance and accumulation of a protease-resistant form of a prion protein (referred to as AScr or PrP-27) in the central nervous system. Similarly, Alzheimer's disease, another neurodegenerative disorder, is characterized by congophilic angiopathy, neuritic plaques and neurofibrillary tangles, all of which have the characteristics of amyloids. In this case, the plaques and blood vessel amyloid is formed by the beta protein. In other systemic diseases such as adult-onset diabetes, the protein is amylin, in complications of long-term hemodialysis , the protein is beta-2-microglobulin, in sequelae of long-standing inflammation, the protein is serum amyloid A (SAA), and in plasma cell dyscrasias, amyloids are characterized by the accumulation of light chains systemically. In each of these cases, a different amyloidogenic protein is involved in amyloid deposition.
Once these amyloids have formed there is no generally accepted therapy or treatment to dissolve the deposits in situ. There is, therefore, an urgent need for therapeutic agents which can either inhibit the formation or growth of amyloid or dissolve amyloid deposits once formed. Co-pending U.S. patent application Ser. No. 08/403,230 describes methods and compositions of sulfated and sulfonated compounds, or functional equivalents thereof, useful in the treatment of amyloidosis in vivo.
One difficulty encountered in identification of therapeutic agents for the treatment of amyloidosis is the lack of rapid, general screening assays for such agents. U.S. Pat. No. 5,164,295 describes a screening assay which measures the ability of a compound to inhibit the interaction between an amyloid protein and an extracellular matrix protein. U.S. Pat. No. 5,348,963 describes an assay which screens compounds based on their ability to alter the intracellular processing of amyloid precursor proteins in mammalian cells in cell culture. Co-pending U.S. patent application Ser. No. 08/403,230 describes a mouse model of amyloidosis which is used for screening for compounds which have the ability to decrease amyloid formation in vivo.
Another difficulty encountered in searching for treatments for amyloidosis is that the mechanism of amyloid fibril formation, although extensively studied in vivo (see, e.g., R. Kisilevsky and I. Young (1994) in G. Husby, ed. "Clinical Rheumatology: Vol. 8, No. 3, Reactive Amyloidosis and the Acute Phase Response" London: Bailliere Tindall, pp. 613-626; E. Gruys and F. W. J. J. Snel (1994) in Husby, ed., op. cit., pp.599-611) and in vitro (see, e.g., G. G. Glenner et al., (1971) Science 174:712; E. M. Castano et al. (1986) Biochem. Biophys. Res. Commun. 141:782; D. A. Kirschner et al. (1987) Proc Natl. Acad. Sci. USA 84:6953), has not been completely elucidated. In general, in vitro conditions used to cause amyloid fibril formation have not been similar to physiological conditions. The in vitro methods known in the art usually require high amyloid protein concentrations, unnatural pH ranges, or strong solvents to cause amyloid fibril formation ( see, e.g., I. B. Kingston et al., (1995) Nature Med., 1:138-142; Glenner et al, (1971) op. cit.). Thus, the amyloid fibrils formed by these methods may not reflect the structure of fibrils formed in vivo, and the conclusions drawn from structural studies of such in vitro-formed fibrils may not be applicable to fibrils formed by amyloidogenic conditions in vivo.
This invention is based, at least in part, on the discovery of amyloid-enhancing compounds which are capable of increasing the rate of amyloid formation both in vivo and in vitro. The invention pertains to methods useful in increasing amyloid formation in an animal. The methods of the invention find use in animal models of amyloidosis because the induction time or formation time of amyloid formation in the animal models can be decreased. The invention also pertains to methods of inducing amyloid fibril formation in vitro.
In one aspect, the invention features a method of increasing amyloid deposition in a mammal. The method comprises administering to the mammal an effective amount of an amyloid-enhancing compound. In preferred embodiments, the amyloid-enhancing compound is a sulfonated aliphatic or aromatic compound. In a more preferred embodiment, the amyloid-inducing compound has an aromatic moiety comprising at least two sulfonate moieties. Preferred amyloid-enhancing compounds include 2-sulfobenzoic acid, benzene-1,2-disulfonic acid, benzene-1,3-disulfonic acid, benzene-1,4-disulfonic acid, or pharmaceutically acceptable salts thereof. Particularly preferred amyloid-enhancing compounds include 4,5-dihydroxy-1,3-benzenedisulfonic acid, 2,5-dihydroxy-1,4-benzenedisulfonic acid, 2,5-dimethoxy-1,4-benzenedisulfonic acid, and their pharmaceutically acceptable salts. The compounds of the invention are administered to a subject by a route which is effective for enhancement of amyloid deposition. Suitable routes of administration include subcutaneous, intravenous and intraperitoneal injection. The compounds of the invention have been found to be effective at enhancing amyloid deposition when administered orally. Accordingly, a preferred route of administration is oral administration. The compounds can be administered with a pharmaceutically acceptable vehicle.
In another aspect, the invention features a method of forming amyloid fibrils from an amyloidogenic peptide. The method features contacting an amyloidogenic peptide with an effective amount of an amyloid-enhancing compound forming amyloid fibrils.
In still another aspect the invention features a method of screening for agents useful for treating amyloidosis. The method comprises providing a reaction mixture which includes a solution of an amyloidogenic peptide, an amyloid-enhancing compound, and an agent potentially useful for treating amyloidosis, under conditions such that, in the absence of the agent potentially useful for treating amyloidosis, amyloid fibrils would form, and observing formation or absence of amyloid fibrils.
In yet another aspect, the invention provides an animal having non-naturally occurring amyloid deposits. The animal is treated with an effective amount of an amyloid-enhancing compound such that the animal has non-naturally occurring amyloid deposits.
FIG. 1 shows circular dichroism (CD) spectra of Aβ in the absence and presence of WAS-20 (2,5-dihydroxy-1,4-benzenedisulfonic acid).
FIG. 2 shows circular dichroism (CD) spectra of Aβ in the absence and presence of WAS-21 (4,5-dihydroxy-1,3-benzenedisulfonic acid).
This invention pertains to methods useful in increasing amyloid formation in an animal. These methods of the invention find use in animal models of amyloidosis. The invention also pertains to methods of inducing amyloid fibril formation in vitro. The in vitro methods of the invention find application in the study of amyloidogenesis and amyloid fibril structure.
For convenience, certain terms used throughout the specification and appended claims are first defined.
The term "amyloid-enhancing compound", as used herein, means a compound which is capable of enhancing the rate or amount of amyloid deposition in vivo or in vitro. A compound can be tested to determine whether it is an amyloid-enhancing compound according to the methods described in the Exemplification, infra. Preferred amyloid-enhancing compounds for use in vivo do not exhibit significant toxicity when administered to an animal at levels sufficient to increase amyloid deposition in vivo. Preferred amyloid-enhancing compounds for use in vivo, when tested in the mouse model described in Example 1, infra, increase the rate or amount of amyloid deposited in mouse spleen by at least about 10 percent, more preferably at least about 20 percent, and still more preferably at least about 30 percent compared to control. It will be understood that increases in amyloid deposition can occur at certain dosages or concentrations of an amyloid-enhancing compound, but not at other concentrations or dosages. In light of the teaching herein (see, e.g., Example 1), the skilled artisan will be able to determine suitable dosages or concentrations with no more than routine experimentation. Preferred amyloid-enhancing compounds include compounds which have an aromatic moiety and at least two anionic moieties, e.g. attached to the aromatic moiety. Examples of preferred amyloid-enhancing compounds include 2-sulfobenzoic acid, 1,2-benzene-disulfonic acid, 1,3-benzene-disulfonic acid, 1,4-benzene-disulfonic acid, and their pharmaceutically acceptable salts. Particularly preferred amyloid enhancing compounds include 4,5-dihydroxy-1,3-benzene-disulfonic acid, 2,5-dihydroxy-1,4-benzenedisulfonic acid, 2,5-dimethoxy-1,4-benzenedisulfonic acid, and their pharmaceutically acceptable salts.
The terms "amyloidogenic peptide" or "amyloidogenic protein", as used herein, refer to peptides which are capable of forming amyloid deposits. Amyloids have been categorized by the type of amyloidogenic protein contained within the amyloid. Non-limiting examples of amyloids, and their amyloidogenic proteins, are as follows (with the associated disease in parentheses after the amyloidogenic protein): β-amyloid (Aβ) (Alzheimer's disease, Down's syndrome, hereditary cerebral hemorrhage amyloidosis Dutch!); amyloid A (AA) (reactive secondary! amyloidosis, familial Mediterranean Fever, familial amyloid nephropathy with urticaria and deafness Muckle-Wells syndrome!); amyloid κ L-chain or amyloid λ L-chain (idiopathic primary!, myeloma or macroglobulinemia-associated); Aβ2M (chronic hemodialysis); transthyretin amyloid (TTR) (familial amyloid polyneuropathy Portuguese, Japanese, Swedish!, familial amyloid cardiomyopathy Danish!, isolated cardiac amyloid, systemic senile amyloidosis); AIAPP or amylin (adult onset diabetes, insulinoma); atrial naturetic factor (isolated atrial amyloid); procalcitonin (medullary carcinoma of the thyroid); gelsolin (familial amyloidosis Finnish!); cystatin C (hereditary cerebral hemorrhage with amyloidosis Icelandic!); AApoA-I (familial amyloidotic polyneuropathy Iowa!); AApoA-II (accelerated senescence in mice); fibrinogen-associated amyloid; lysozyme-associated amyloid; and AScr or PrP-27 (Scrapie, Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome, bovine spongiform encephalitis). It will be understood that other natural or non-natural proteins or peptides which are capable of forming amyloid or amyloid-like fibrils in vivo or in vitro are also considered to be amyloidogenic peptides for the purposes of the present invention. For example, certain fragments of amyloidogenic peptides can form amyloid fibrils (see, e.g., P. D. Gorevic et al., (1986) Biochem. Biophys. Res. Commun. 147:854) and thus are considered to be amyloidogenic peptides for the purposes of the present invention.
The term "an animal having non-naturally occurring amyloid deposits", as used herein, refers to an animal which has deposits of amyloid which do not normally occur in that animal under natural conditions, and which are in excess of the amyloid deposits which occur when the animal is treated with an inflammatory stimulus and amyloid enhancing factor (AEF) (see, e.g. R. Kisilevsky and L. Boudreau, (1983) Lab. Invest., 48, 53-59). For example, Swiss white mice do not normally suffer from amyloid deposits, but Swiss white mice treated with the amyloid-enhancing compounds of the present invention have enhanced amyloid deposition compared to control animals (see Example 1).
The term "anionic group", as used herein, refers to a moiety which has a net negative charge. In preferred embodiments, the anioic group has a negative charge at physiological pH. Exemplary anionic groups include sulfonate, sulfate, carboxylate, phosphate, phosphonate, and the like. Preferred anionic groups include carboxylate and sulfur containing moieties (e.g., sulfonate, sulfate and the like).
In one aspect, the invention features a method for increasing amyloid deposition in an animal. Animals which exhibit amyloidosis are useful in screening assays for compounds which inhibit amyloidosis in vivo, as described in R. Kisilevsky et al., (1995) Nature Med. 1:143-148, and in copending U.S. patent application Ser. No. 08/403,230, the disclosures of both of which are hereby incorporated by reference. Amyloidosis is induced in mice by treating the animal with an inflammatory stimulus, in combination with amyloid enhancing factor (AEF), as described in Kisilevsky and Boudreau, (1983) op. cit. (see Example 1). To induce long-lasting amyloidosis, repeated injections of the inflammatory stimulus are often required. Furthermore, in some animal models of amyloidosis, long periods of time must elapse between administration of an amyloid-inducing stimulus and the deposition of amyloid (Kisilevsky and Boudreau, ibid.).
The methods of the present invention make possible the development of amyloid deposits in animals in a shorter period of time and/or result in an increase in amyloid deposits over a selected period of time when compared to a control. This makes possible more rapid screening of compounds in animal models of amyloidosis (for example, the mouse model described herein). Such rapid screening is particularly desirable when large numbers of candidate compounds are to be tested, as, for example, when structure-activity relationships are being probed, or when searching for compounds for further modification. Moreover, the increased amount of amyloid deposition seen in animals treated with amyloid-enhancing compounds may result in increased sensitivity of assays for compounds effective in the treatment of amyloidosis. Compounds which have a relatively modest effect on amyloid deposition in vivo may nevertheless be useful therapeutically, or may provide important structure-activity information.
The mechanism by which the amyloid-enhancing compounds described herein increase amyloid deposition in vivo is not precisely known. It is known, however, that sulfated and sulfonated compounds effective for the treatment of amyloidosis in vivo (i.e., compounds that decrease amyloid deposition) inhibit an interaction between an amyloidogenic protein and a constituent of basement membrane, and thereby inhibit amyloid deposition (see, e.g., U.S. patent application Ser. No. 08/403,230 and references cited therein). The constituent of basement membrane is a glycoprotein or proteoglycan, preferably heparan sulfate proteoglycan (HSPG). Without being bound by theory, it is believed that the amyloid-enhancing compounds described herein enhance interactions either between an amyloidogenic protein and a component of basement membrane, or between monomers of the amyloidogenic protein, and thereby enhance amyloid deposition in vivo.
The methods of the invention also provide increased amyloid deposition in vitro. The mechanism by which the amyloid-enhancing compounds described herein increase amyloid deposition in vitro is also not precisely known.
The above-described mouse model of amyloidosis is a useful model of amyloidosis caused by serum amyloid A (SAA). The present invention makes possible the development of animal models of amyloidosis caused by other amyloidogenic proteins and for which no animal models currently exist.
In another embodiment, the invention features a method of increasing amyloid deposition in vitro. The in vitro study of amyloid fibril formation is important to the ultimate elucidation of the causes of amyloid formation in vivo. Co-pending U.S. patent application Ser. No. 08/372,178 (the disclosure of which is hereby incorporated by reference) discloses assay methods useful for studying the effects of test compounds on amyloid deposition in vitro. However, most previous studies of in vitro amyloid fibril formation have used conditions which are not similar to conditions found in vivo. For example, amyloid formation in vitro has been induced by use of concentrations of amyloidogenic proteins which are orders of magnitude greater than are found in vivo. As noted above, non-physiological pH ranges and organic solvents have also been employed to cause amyloid fibril formation. Furthermore, certain amyloidogenic proteins are resistant to fibrillogenesis in vitro, and the study of these resistant amyloidogenic proteins has heretofore been hindered by difficulties encountered in inducing fibril formation.
The use of non-physiological conditions may lead to misinterpretations. The nature of the interactions between HSPG and amyloidogenic proteins is not completely understood. Crystallographic studies of amyloid fibrils formed in vitro are a potentially powerful method of studying these interactions; however, the structure of the fibrils may be affected by the conditions used for fibril formation. For example, the structure of amyloid fibrils deposited from a solution at pH 5.6 (the pI of amyloid beta protein fragment 1-28) may not be the same as the structure of fibrils deposited at pH 7. Fibrils deposited from protein solutions of differing concentration may also not be identical. The concentration of amyloidogenic peptides found in vivo, such as serum amyloid A (SAA), varies, but may be as low as 1-5 μg/ml, under normal circumstances, to as high as about 0.5-1 mg/ml during an inflammatory reaction. For these reasons, conditions for fibril formation which more closely resemble conditions found in vivo are desirable.
The present invention provides a method of inducing amyloid fibril formation in vitro under conditions which more closely approximate physiological conditions (see Example 2). The structure of the fibrils formed in vitro by the methods provided herein is believed to more closely resemble the structure of amyloid fibrils found in subjects suffering from amyloidosis. Thus, in a preferred embodiment, the method of inducing amyloid fibril formation in vitro according to the present invention is carried out at a pH between about 6.5 and about 7.5, more preferably at a pH between about 6.2 and 7.2, and most preferably at a pH of about 7. In a preferred embodiment, the method of inducing amyloid fibril formation in vitro according to the present invention is carried in a solution which is substantially free of non-aqueous solvents. In a preferred embodiment, the method of inducing amyloid fibril formation in vitro according to the present invention is carried out on a solution of amyloidogenic peptide which has a concentration of less than about 2 mg/ml, more preferably less than about 1.5 mg/ml, and still more preferably at a concentration less than about 1 mg/ml.
An advantage of the methods according to the present invention is that the formation of amyloid fibrils is more rapid in the presence of an amyloid-enhancing compound than in the absence of the amyloid-enhancing compound. As described in Example 2, amyloid fibril formation can be a slow process, requiring up to three days. The subject methods increase the speed of amyloid formation and decrease the time necessary for fibril formation.
Interestingly, the amyloid-enhancing compounds described in Examples 1 and 2 share certain structural features in common with compounds known to decrease amyloid deposition in vivo (i.e., at least one anionic sulfonate group, see Example 1). Furthermore, the amyloid-enhancing compounds generally comprise at least one aromatic ring, with a sulfonate directly bonded to the ring. Without being bound by theory, the presence of two anionic moieties on an aromatic ring may be important for amyloid-enhancing activity.
In another aspect, the invention provides a method of screening for agents useful for treating amyloidosis. In this screening method, a combination of an amyloidogenic peptide and an amyloid-enhancing compound is provided under conditions which allow amyloid fibrils to form; a test agent is introduced into the combination forming a screening medium; and the presence or absence of amyloid fibril formation within the screening medium is detected as an indication of the ability of the test agent to treat amyloidosis. The ability of a compound to prevent amyloid deposition in vitro is related to the ability of that compound to prevent amyloid deposition in vivo (see e.g., Examples 1-3, infra).
In another aspect, the invention provides an animal or mammal having non-naturally occurring amyloid deposits, comprising an animal treated with an amyloid-enhancing compound such that the animal has non-naturally occurring amyloid deposits. Animals having non-naturally occurring amyloid deposits are useful as animal models of amyloidosis, and as such are valuable for screening compounds which are useful for treating amyloidosis. Examples of animals or mammals include mice, rats, dogs, cats, pigs, horses, primates and the like.
The invention is further illustrated by the following examples, which should not be construed as further limiting the subject invention. All references, issued patents, and patent applications cited throughout this application are incorporated herein by reference.
Aβ is a 40 amino acid protein associated with Alzheimer's disease. Aβ peptide was prepared and purified as described in Fraser, P. E. et al., Biochemistry 31, 10716 (1992). Briefly, the peptide was synthesized by standard solid-phase techniques and purified by HPLC according to well known procedures.
The sulfated and sulfonated compounds used in the examples below are commercially available (e.g. Sigma Chemical Co., St. Louis, Mo., or Aldrich Chemical Co., Milwaukee, Wis.) and/or can be synthesized by standard techniques known in the art (see, e.g., Stone, G. C. H. (1936) J. Am. Chem. Soc., 58:488).
Swiss white mice weighing 25-30 g were given Amyloid Enhancing Factor (AEF) and AgNO3 as described previously (Kisilevsky, R. and Boudreau, L. (1983) "The kinetics of amyloid deposition: I. The effect of amyloid enhancing factor and splenectomy"Lab. Invest., 48, 53-59), to induce amyloidosis. Twenty four (24) hours later they were divided into groups. One group served as a control and was maintained on standard laboratory mouse chow and tap water ad lib. The test groups received standard chow but their water contained 20 or 50 mM of one of the compounds listed in Table 2, below. One compound, taurine, was tested at concentrations of 5 mM, 10 mM, 20 mM, and 50 mM. All compounds were dissolved in water containing 1.0% sucrose, and the pH adjusted to 7. Water intake was approximately equivalent for all groups. All animals were sacrificed on day six (6) of the experiment, their spleens collected, prepared for sectioning, spleen sections stained with Congo red (Puchtler, H., et al (1983) "Application of Thiazole Dyes to Amyloid under Conditions of Direct Cotton Dyeing: Correlation of Histochemical and Chemical Data" Histochemistry, 77, 431-445), and the percent area occupied by amyloid assessed by an image analysis apparatus and program (MCID M2, Imaging Research Inc., Brock University, St. Catherines, Ontario, Canada).
The results are summarized in Table 1, below.
TABLE 1______________________________________Effect of Sulfated and Sulfonated Compoundson AA Amyloid Deposition In vivo in Mouse Spleen Concentration Amyloid StandardCompound (mM) Deposition* Error______________________________________1,5-Pentanedisulfonate† 50 76 11 20 60 201,6-Hexanedisulfonate† 50 117 17 20 98 261,2-Ethanediol disulfate† 50 8 2 20 36 101,3-Propanediol disulfate† 50 11 4 20 32 111,4-Butanediol disulfate† 50 54 22 20 44 11Taurine 50 68 15 20 45 23 10 34 16 5 95 33WAS-10 50 79 22 20 80 23WAS-11 50 114 20 114WAS-12 50 55 20 74WAS-13 50 81 20 63WAS-14 50 135 27 20 83 28WAS-15 50 56 13 20 102 24WAS-16 50 48 12 20 98 30WAS-17 50 60 21 20 54 31WAS-18 50 110 35 20 97 50WAS-19 50 61 13 20 117 28WAS-20 50 192 37 20 119 19WAS-21 50 158 19 20 130 28WAS-22 50 83 19 20 155 28WAS-23 50 66 12 20 94 11WAS-24 50 103 19 20 110 15WAS-27 50 100 18 20 86 30WAS-28 50 56 20 53WAS-34 50 53 20 59WAS-35 50 51WAS-36 50 71WAS-37 50 100 20 102WAS-38 50 81______________________________________ †As the sodium salt. *Amyloid deposition is given as a percentage of untreated control. All measurements are the average of 3-5 animals.
The results indicate that animals treated with sodium 1,2-ethanediol disulfate or sodium 1,3-propanediol disulfate had at least about a 65% decrease in amyloid deposition at 20 mM and at least about a 90% decrease in amyloid deposition at 50 mM. Animals treated with sodium 1,4-butanediol disulfate (50 mM), sodium 1,5-pentanedisulfonate ((50 mM), taurine (sodium 2-amino-ethanesulfonate) (10-20 mM), 3-(cyclohexylamino)-1-propanesulfonate (WAS-12) (50 mM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonate (WAS-13) (20 mM), 3-(N-morpholino)propanesulfonic acid (MOPS) (WAS-15) or its sodium salt (WAS-16) (50 mM), sodium tetrahydro-3,4-thiophene-1,1-dioxide-3,4-disulfonate trihydrate (WAS-19), sodium 4-hydroxybutane-1-sulfonate (WAS-17) (50 mM), sodium 1,3,5-pentanetriol trisulfate (WAS-28) (20 and 50 mM), 2-aminoethyl hydrogen sulfate (WAS-34) (20 and 50 mM), Indigo Carmine (WAS-35) (50 mM) had at least approximately a 40% decrease in amyloid deposition compared to untreated control animals. Taurine caused decreased amyloid deposition at concentrations of 10-20 mM, but had less effect at 5 mM or 50 mM.
The results indicate that certain compounds increased the amount of amyloid deposition in vivo. Administration of 4,5-dihydroxy-1,3-benzenedisulfonic acid (WAS-21) or 2,5-dihydroxy-1,4-benzenedisulfonic acid (WAS-20) resulted in increased levels of splenic amyloid. Without wishing to be bound by theory, it is believed that two aromatic sulfonate moieties are important to the amyloid-enhancing activity of the subject compounds (see below).
Samples of amyloid were prepared for electron micrographic (EM) examination as described in Kisilevsky et al. Nature Med (1995), loc. cit.. Briefly, negatively-stained fibrils of Aβ were prepared by floating pioloform carbon-coated grids on peptide solutions (1-2 mg/ml, 20 mM Tris-HCl, pH 7) that had been preincubated for 72 hours at 37° C. to ensure extensive Aβ polymerization. A control sample contained no test compound. Test compounds were added at ten-fold molar excess to preformed amyloid fibrils with a subsequent incubation for 24 hours at 37° C. After the grids were blotted and air-dried, the samples were stained with 1% phosphotungstic acid (w/v) and visualized on a Hitachi H-7000 electron microscope operated at 75 kV. Fibril dimensions were calibrated using tropomyosin paracrystals.
Aβ fibrils were generated and then treated with WAS-6 (1,3-propanediol disulfate, sodium salt). The fibrils treated with WAS-6 showed a marked reduction in numbers, attenuation in length, and had a much coarser appearance than the control fibrils. Thus, WAS-6 can be classified as an amyloid inhibitor.
Amyloid fibrils were then generated and treated with WAS-20 (2,5-dihydroxy-1,4-benzenedisulfonic acid). EM examination of the fibrils formed showed increased amounts of fine fibrils, compared to the control sample. Thus, WAS-20 can be classified as an amyloid enhancer in vitro. In a similar experiment, WAS-21 was classified as an amyloid enhancer in vitro. These results are consistent with the in vivo assay performed in Example 1, supra. WAS-46 (2,5-dimethoxy-1,4-benzenedisulfonic acid), a methylated derivative of WAS-20, was also found to be an amyloid enhancer in vitro. This result demonstrates that a free phenolic hydroxyl group is not necessary for amyloid enhancing activity.
Amyloid fibrils were then generated and treated with WAS-52 (4-amino-3-hydroxy-1-naphthalenesulfonic acid) or WAS-53 (3,4-diamino-1-naphthalenesulfonic acid. EM examination of the fibrils formed showed no increase in number of fibrils compared to a control sample. Thus, WAS-52 and WAS-53 are not amyloid enhancers in vitro.
β-pleated sheet secondary structure is characteristic of all amyloid deposits, so destabilization of β-sheet formation may reduce the rate of amyloid deposition; conversely, compounds which increase β-sheet formation may increase the rate of amyloid deposition. Determination of amyloid protein conformation by CD has been reported (McCubbin, W. D. et al., Biochem J. 256, 775 (1988)); the amount of β-sheet present in a sample was related to the minimum at about 218 nm.
All CD experiments were performed on a Jasco J-720 instrument. The cell was maintained at 25° C. using a circulating water bath. Computer-averaging of traces was performed to improve signal-to-noise ratios. The solvent signal was subtracted.
CD experiments were performed for each test compound according to the following procedure:
A stock solution of purified peptide was made by dissolving the peptide in phosphate-buffered saline (PBS) to a concentration of 2 mg/ml. A test solution was made for each potential therapeutic agent (test compound) as shown below:
______________________________________Aβ stock solution 25 μlTest compound (20 mg/ml) 2.5 μlDistilled water 2.5 μl10 mM Tris buffer, pH 7 370 μl______________________________________
The control sample had no test compound, and a total of 5 μl distilled water was added. The test solution was incubated for either 0 or 24 hours at 37° C. before CD measurement.
FIG. 1 shows the CD spectrum of Aβ in the presence and the absence of compound WAS-20 (2,5-dihydroxy-1,4-benzenedisulfonic acid). The spectra show the effect of WAS-20 on the secondary structure of the amyloid peptide. The size of the minimum near 218 nm is diagnostic of the presence of β-pleated sheet. The amount of β-pleated sheet by this measurement is about 20% greater in the presence of WAS-20; as previously noted, compounds which increase β-sheet formation may increase the rate of amyloid deposition. WAS-20 also increases the amount of light-scattering from the sample, as evidenced by the greatly increased noise at shorter wavelengths; this scattering is believed to be the result of larger aggregated particles produced by the test compound. Thus, WAS-20 can be classified as an amyloid enhancer by this in vitro assay. Similar results were obtained with WAS-21 (4,5-dihydroxy-1,3-benzenedisulfonic acid), as shown in FIG. 2. Although the change in the minimum near 218 nm is not as large for WAS-21 as for WAS-20, the increased light-scattering due to larger aggregated particles is evident. These results are consistent with the in vivo and in vitro assays performed in Examples 1 and 2, supra.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4816416 *||Mar 3, 1987||Mar 28, 1989||Paul Averback||Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions|
|US4919915 *||Feb 27, 1989||Apr 24, 1990||Paul Averback||Method for detecting the ability to prevent red-to-green congophilic birefringence|
|US5164295 *||Mar 6, 1991||Nov 17, 1992||The Upjohn Company||Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds|
|US5216127 *||Jul 12, 1991||Jun 1, 1993||Kanegafuchi Kagaku Kogyo Kabushiki Kaisha||Adsorbent for serum amyloid protein|
|US5221607 *||Oct 29, 1991||Jun 22, 1993||Scios Nova Inc.||Assays and reagents for amyloid deposition|
|US5262303 *||Oct 11, 1990||Nov 16, 1993||Trustees Of Boston University||Ligand/anti-ligand assays for adherent proteins|
|WO1994022437A2 *||Mar 29, 1994||Oct 13, 1994||Queen's University At Kingston||Method for treating amyloidosis|
|WO1994022885A1 *||Mar 29, 1994||Oct 13, 1994||Queen's University At Kingston||Anticoagulant compounds|
|1||*||Casta n o, E.M., et al, In Vitro Formation of Amyloid Fibrils from Two Synthetic Peptides of Different Lengths Homologous to Alzheimer s Disease Protein , Biochemical and Biophysical Research Communications 141:782 789 (1986).|
|2||Castano, E.M., et al, "In Vitro Formation of Amyloid Fibrils from Two Synthetic Peptides of Different Lengths Homologous to Alzheimer's Disease β-Protein", Biochemical and Biophysical Research Communications 141:782-789 (1986).|
|3||Caughey, B., et al., "Scrapie-associated PrP Accumulation and Its Inhibition: Revisiting the Amyloid-Glycosaminoglycan Connection", Annals New York Academy of Sciences 290-295.|
|4||*||Caughey, B., et al., Scrapie associated PrP Accumulation and Its Inhibition: Revisiting the Amyloid Glycosaminoglycan Connection , Annals New York Academy of Sciences 290 295.|
|5||Connors, L.H., et al., "In Vitro Formation of Amyloid Fibrils from Intact σ2 Microglobulin", Biochemical and Biophysical Research Communications 3: 1063-1068 (1985).|
|6||*||Connors, L.H., et al., In Vitro Formation of Amyloid Fibrils from Intact 2 Microglobulin , Biochemical and Biophysical Research Communications 3: 1063 1068 (1985).|
|7||Glenner, G.G., et al., "Creation of `Amyloid` Fibrils from Bence Jones Proteins in vitro", National Institutes of Health 174: (Nov. 1971).|
|8||*||Glenner, G.G., et al., Creation of Amyloid Fibrils from Bence Jones Proteins in vitro , National Institutes of Health 174: (Nov. 1971).|
|9||Glombitza, K.W., et al., "Phenolsulphate esters from Phaeophyceae", Bull. Liaison-Groupe Polyphenols. vol. 14, pp. 244-247 (1988).|
|10||*||Glombitza, K.W., et al., Phenolsulphate esters from Phaeophyceae , Bull. Liaison Groupe Polyphenols. vol. 14, pp. 244 247 (1988).|
|11||Gorevic, P.D., et al., "Ten to Fourteen Residue Peptides of Alzheimer's Disease Protein are Sufficient for Amyloid Fibril Formation and its Characteristic Xray Diffraction Pattern", Biochemical and Biophysical Research Communications 147:854-862 (1987).|
|12||*||Gorevic, P.D., et al., Ten to Fourteen Residue Peptides of Alzheimer s Disease Protein are Sufficient for Amyloid Fibril Formation and its Characteristic Xray Diffraction Pattern , Biochemical and Biophysical Research Communications 147:854 862 (1987).|
|13||Gruys, E., et al, "Animal models for reactive amyloidosis", Bailliere's Clinical Rheumatology 8: 599-611 (1994).|
|14||*||Gruys, E., et al, Animal models for reactive amyloidosis , Bailli e re s Clinical Rheumatology 8: 599 611 (1994).|
|15||*||International Search Report dated Oct. 18, 1996.|
|16||Kirschner, D.A., et al., "Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils in vitro", Proc. Natl. Acad. Sci USA 84: 6953-6957 1987.|
|17||*||Kirschner, D.A., et al., Synthetic peptide homologous to protein from Alzheimer disease forms amyloid like fibrils in vitro , Proc. Natl. Acad. Sci USA 84: 6953 6957 1987.|
|18||*||Kisilevsky et al., Critical Reviews in Clinical Laboratory Sciences, vol. 29:1, pp. 59 82, 1992.|
|19||Kisilevsky et al., Critical Reviews in Clinical Laboratory Sciences, vol. 29:1, pp. 59-82, 1992.|
|20||Li, X.A., et al., "Binding of serum amyloid P component heparin in human serum", Biochimica et Biophysica Acta 1201: 143-148 (1994).|
|21||*||Li, X.A., et al., Binding of serum amyloid P component heparin in human serum , Biochimica et Biophysica Acta 1201: 143 148 (1994).|
|22||Magnus, J.H., et al., "Proteoglycans, glycosaminoglycans and amyloid deposition", Bailliere's Clinical Rheumatology 8: 575-597 (1994).|
|23||*||Magnus, J.H., et al., Proteoglycans, glycosaminoglycans and amyloid deposition , Bailli e re s Clinical Rheumatology 8: 575 597 (1994).|
|24||Merlini, G., "Treatment of Primary Amyloidosis" Seminars in Hematology 32: 60-79 (1995).|
|25||*||Merlini, G., Treatment of Primary Amyloidosis Seminars in Hematology 32: 60 79 (1995).|
|26||Nitta A., et al, "β-Amyloid protein-induced Alzheimer's disease animal model", Neuroscience letters 170: 63-66 (1994).|
|27||*||Nitta A., et al, Amyloid protein induced Alzheimer s disease animal model , Neuroscience letters 170: 63 66 (1994).|
|28||Ragan, M., "Phenol sulfate esters: ultraviolet, infrared, 1 H and 13 C nuclear magnetic resonance spectroscopic investigation", Can. J. Chem. vol. 56, No. 20, pp. 2681-2685 (1978).|
|29||Ragan, M., et al. "Paired-Ion Reversed-Phase High-Performance Liquid Chromotography of Phenol Sulfater in Synthetic Mixtures, Algal Extracts and Urine", Journal of Chromatography, vol. 178, pp. 505-513 (1979).|
|30||*||Ragan, M., et al. Paired Ion Reversed Phase High Performance Liquid Chromotography of Phenol Sulfater in Synthetic Mixtures, Algal Extracts and Urine , Journal of Chromatography, vol. 178, pp. 505 513 (1979).|
|31||*||Ragan, M., Phenol sulfate esters: ultraviolet, infrared, 1 H and 13 C nuclear magnetic resonance spectroscopic investigation , Can. J. Chem. vol. 56, No. 20, pp. 2681 2685 (1978).|
|32||Schwarzman, A.L., et al. "Transthyretin sequesters amyloid β-protein and prevents amyloid formation", Proc. Natl. Acad. Sci. USA 91: 8638-8372 (1994).|
|33||*||Schwarzman, A.L., et al. Transthyretin sequesters amyloid protein and prevents amyloid formation , Proc. Natl. Acad. Sci. USA 91: 8638 8372 (1994).|
|34||*||Snow et al., Neuron, vol. 12: 1, pp. 219 234, 1994.|
|35||Snow et al., Neuron, vol. 12: 1, pp. 219-234, 1994.|
|36||*||WHO IUIS Nomenclature Sub Committee, Nomenclature of amyloidosis , Bulletin of the World Health Organization 71:105 108 (1993).|
|37||WHO-IUIS Nomenclature Sub-Committee, "Nomenclature of amyloidosis", Bulletin of the World Health Organization 71:105-108 (1993).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5977324 *||Feb 20, 1998||Nov 2, 1999||The Regents Of The University Of California||Process for concentrating protein with disease-related conformation|
|US6221614||Jan 20, 1999||Apr 24, 2001||The Regents Of The University Of California||Removal of prions from blood, plasma and other liquids|
|US6617119||Jul 9, 2001||Sep 9, 2003||The Regents Of The University Of California||Assay for specific strains of multiple disease related conformations of a protein|
|US6620629||Oct 27, 2000||Sep 16, 2003||The Regents Of The University Of California||Method for detecting prions|
|US6719988||Jul 11, 2001||Apr 13, 2004||The Regents Of The University Of California||Antiseptic compositions for inactivating prions|
|US6720355||Jan 22, 2002||Apr 13, 2004||The Regents Of The University Of California||Sodium dodecyl sulfate compositions for inactivating prions|
|US6916419||Mar 21, 2003||Jul 12, 2005||The Regents Of The University Of California||Device for removal of prions from blood, plasma and other liquids|
|US7226609||Dec 12, 2003||Jun 5, 2007||The Regents Of The University Of California||Sodium dodecyl sulfate compositions for inactivating prions|
|US7244764||Jun 18, 2004||Jul 17, 2007||Neurochem (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US7307103||Aug 14, 2003||Dec 11, 2007||The Regents Of The University Of California||Sodium dodecyl sulfate compositions for inactivating prions|
|US7393875 *||May 2, 2003||Jul 1, 2008||Neurochem (International) Limited||Methods and compounds for inhibiting amyloid deposits|
|US7414076||Jun 18, 2004||Aug 19, 2008||Neurochem (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US7445907||Oct 12, 2004||Nov 4, 2008||Ista S.P.A.||Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples|
|US7521481||Feb 26, 2004||Apr 21, 2009||Mclaurin Joanne||Methods of preventing, treating and diagnosing disorders of protein aggregation|
|US7598269||May 30, 2007||Oct 6, 2009||Bellus Health (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US7754761||Feb 16, 2007||Jul 13, 2010||Bellus Health (International) Limited||Sulfonated compounds and compositions for treating amyloidosis|
|US7786174||May 22, 2008||Aug 31, 2010||Bellus Health (International) Limited||Methods and compounds for inhibiting amyloid deposits|
|US8044100||Dec 21, 2005||Oct 25, 2011||Bellus Health Inc.||Methods and compositions for treating amyloid-related diseases|
|US8178580||Apr 17, 2006||May 15, 2012||Kiacta Sarl||Formulations and methods for treating amyloidosis|
|US8372886||Dec 22, 2006||Feb 12, 2013||Kiacta Sarl||Treatment of renal disorders, diabetic nephropathy and dyslipidemias|
|US8642801||Nov 5, 2009||Feb 4, 2014||Bhi Limited Partnership||Methods and compositions for treating amyloid-related diseases|
|US8835654||Sep 20, 2011||Sep 16, 2014||Bhi Limited Partnership||Method and compositions for treating amyloid-related diseases|
|US8859628||Feb 27, 2004||Oct 14, 2014||JoAnne McLaurin||Method for preventing, treating and diagnosing disorders of protein aggregation|
|US9499480||Apr 7, 2014||Nov 22, 2016||Bhi Limited Partnership||Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid|
|US20030180706 *||Mar 21, 2003||Sep 25, 2003||The Regents Of The University Of California||Removal of prions from blood, plasma and other liquids|
|US20040052833 *||Aug 14, 2003||Mar 18, 2004||The Regents Of The University Of California||Sodium dodecyl sulfate compositions for inactivating prions|
|US20040053335 *||Aug 14, 2003||Mar 18, 2004||The Regents Of The University Of California||Method for detecting prions|
|US20040057949 *||Sep 23, 2002||Mar 25, 2004||Depaolis Potito U.||Hemodialysis method for improving immune system function|
|US20040127558 *||Dec 12, 2003||Jul 1, 2004||The Regents Of The University Of California||Sodium dodecyl sulfate compositions for inactivating prions|
|US20040127559 *||Dec 12, 2003||Jul 1, 2004||Prusiner Stanley B.||Sodium dodecyl sulfate compositions for inactivating prions|
|US20040198832 *||Aug 11, 2003||Oct 7, 2004||Queen's University At Kingston||Compositions and methods for treating amyloidosis|
|US20040204387 *||Feb 26, 2004||Oct 14, 2004||Mclaurin Joanne||Methods of preventing, treating and diagnosing disorders of protein aggregation|
|US20040220138 *||Sep 3, 2003||Nov 4, 2004||Neurochem (International) Limited||Methods for modulating neuronal cell death|
|US20040248876 *||May 2, 2003||Dec 9, 2004||Queen's University At Kingston And Neurochem, Inc.||Methods and compounds for inhibiting amyloid deposits|
|US20050038117 *||Jun 18, 2004||Feb 17, 2005||Neurochem (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US20050096385 *||Jun 18, 2004||May 5, 2005||Xianqi Kong||Methods and compositions for treating amyloid-related diseases|
|US20050153380 *||Oct 12, 2004||Jul 14, 2005||Ista Spa||Methods for mass spectrometry detection and quantification of specific target proteins in complex biological samples|
|US20060008494 *||Jun 20, 2005||Jan 12, 2006||The Regents Of The University Of California||Complete inactivation of infectious proteins|
|US20060029977 *||Oct 15, 2004||Feb 9, 2006||Ista Spa||Detection and quantification of prion isoforms in neurodegenerative diseases using mass spectrometry|
|US20060128606 *||Jan 20, 2006||Jun 15, 2006||Dobson Christopher M||Fibrils|
|US20060167057 *||Nov 16, 2005||Jul 27, 2006||Xianqi Kong||Compounds for the treatment of CNS and amyloid associated diseases|
|US20060167095 *||Dec 22, 2005||Jul 27, 2006||Robert Kisilevsky||Method for treating amyloidosis|
|US20060183800 *||Nov 14, 2005||Aug 17, 2006||Xianqi Kong||Methods and fluorinated compositions for treating amyloid-related diseases|
|US20060223855 *||Dec 21, 2005||Oct 5, 2006||Neurochem (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US20060252829 *||Apr 17, 2006||Nov 9, 2006||Denis Garceau||Formulations and methods for treating amyloidosis|
|US20070010573 *||Dec 21, 2005||Jan 11, 2007||Xianqi Kong||Methods and compositions for treating amyloid-related diseases|
|US20070015737 *||Nov 2, 2005||Jan 18, 2007||Neurochem (International) Limited||Compounds for inhibiting diseases and preparing cells for transplantation|
|US20070049638 *||Jul 14, 2006||Mar 1, 2007||Neurochem (International) Limited||Polymorphic forms of 3-amino-1-propanesulfonic acid|
|US20070111970 *||Oct 13, 2006||May 17, 2007||Antonio Cruz||Inositol compounds and uses of same in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, desposition, accumulation or persistence|
|US20070197452 *||Feb 16, 2007||Aug 23, 2007||Mclaurin Joanne||Treatment of amyloid-related diseases|
|US20070238788 *||Dec 22, 2006||Oct 11, 2007||Wendy Hauck||Treatment of renal disorders, diabetic nephropathy and dyslipidemias|
|US20070265334 *||Feb 16, 2007||Nov 15, 2007||Neurochem (International) Limited||Method for treating amyloidosis|
|US20080015180 *||May 30, 2007||Jan 17, 2008||Neurochem (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US20080227767 *||May 22, 2008||Sep 18, 2008||Neurochem (International) Limited||Methods and compounds for inhibiting amyloid deposits|
|US20080262088 *||Dec 21, 2007||Oct 23, 2008||Wendy Hauck||Methods, compounds, and compositions for treating metabolic disorders and diabetes|
|US20080306166 *||Nov 17, 2005||Dec 11, 2008||Mclaurin Joanne||Compositions and Methods For Treatment of Disorders of Protein Aggregation|
|US20090062403 *||May 22, 2008||Mar 5, 2009||Mclaurin Joanne||Compositions and Methods for Treatment of Disorders of Protein Aggregation|
|US20090099100 *||Jul 7, 2008||Apr 16, 2009||Bellus Health (International) Limited||Compositions and methods for treating amyloidosis|
|US20090170957 *||Oct 13, 2006||Jul 2, 2009||Antonio Cruz||Scyllo-inositol derivatives and their use in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence|
|US20090227686 *||Mar 3, 2009||Sep 10, 2009||Mclaurin Joanne||Methods of preventing, treating and diagnosing disorders of protein aggregation|
|US20100093648 *||Oct 9, 2009||Apr 15, 2010||Antonio Cruz||Treatment of macular degeneration-related disorders|
|US20100105631 *||Nov 11, 2009||Apr 29, 2010||Waratah Pharmaceuticals Inc.||Inositol Compounds and Uses of Same in the Treatment of Diseases Characterized by Abnormal Protein Folding or Aggregation or Amyloid Formation, Desposition, Accumulation or Persistence|
|US20100113591 *||Nov 5, 2009||May 6, 2010||Bellus Health (International) Limited||Methods and compositions for treating amyloid-related diseases|
|US20100113613 *||Mar 9, 2007||May 6, 2010||Waratah Pharmaceuticals||cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation|
|US20100144891 *||Apr 11, 2008||Jun 10, 2010||Mclaurin Joanne||Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis|
|US20100168250 *||Apr 11, 2008||Jul 1, 2010||Antonio Cruz||Use of cyclohexanehexol derivatives in the treatment of ocular disease|
|US20100173960 *||Sep 20, 2007||Jul 8, 2010||Antonio Cruz||The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases|
|US20100292157 *||Nov 22, 2007||Nov 18, 2010||Antonio Cruz||Combination Treatments for Alzheimer's Disease and Similar Diseases|
|US20100331267 *||Apr 11, 2008||Dec 30, 2010||Mclaurin Joanne||Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies|
|US20110028719 *||May 18, 2007||Feb 3, 2011||Jacek Slon-Usakiewicz||Screening methods for amyloid beta modulators|
|US20110105626 *||Apr 11, 2008||May 5, 2011||Mclaurin Joanne||Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases|
|US20110201694 *||Sep 15, 2010||Aug 18, 2011||Mclaurin Joanne||Compositions and Methods for Treatment of Disorders of Protein Aggregation|
|WO1999042487A1 *||Feb 4, 1999||Aug 26, 1999||The Regents Of The University Of California||Process for concentrating protein with disease-related conformation|
|WO2000043782A2 *||Dec 17, 1999||Jul 27, 2000||The Regents Of The University Of California||Removal of prions from blood, plasma and other liquids|
|WO2000043782A3 *||Dec 17, 1999||Jan 18, 2001||Stanley B Prusiner||Removal of prions from blood, plasma and other liquids|
|WO2002082919A1 *||Apr 17, 2002||Oct 24, 2002||Femtolink Biotechnologies Llc||Detection and quantification of prion isoforms in neurodegenerative diseases using mass spectrometry|
|U.S. Classification||424/9.2, 424/78.35, 424/78.31, 435/7.95, 435/7.92, 435/7.93, 514/772.4, 800/9, 435/7.8, 530/350|
|International Classification||A61K31/185, A61K31/00, G01N33/68, A01K67/027|
|Cooperative Classification||A61K31/185, A61K31/00, G01N33/6896, G01N2800/52, A61K31/7024, A01K67/027|
|European Classification||A61K31/00, G01N33/68V2, A61K31/185, A01K67/027, A61K31/7024|
|Nov 22, 1995||AS||Assignment|
Owner name: NEUROCHEM, INC, CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FRASER, PAUL;REEL/FRAME:007736/0025
Effective date: 19950929
Owner name: QUEEN S UNIVERSITY AT KINGSTON, CANADA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KISILEVSKY, ROBERT;SZAREK, WALTER;WEAVER, DONALD;AND OTHERS;REEL/FRAME:007734/0741;SIGNING DATES FROM 19950816 TO 19950823
|Apr 5, 1999||AS||Assignment|
Owner name: QUEEN S UNIVERSITY AT KINGSTON, CANADA
Free format text: RE-RECORD TO CORRECT THE NAME OF THE FOURTH INVENTOR, PREVIOUSLY RECORDED ON REEL 7734, FRAME 0741,ASSIGNOR CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST.;ASSIGNORS:KISILEVSKY, ROBERT;SZAREK, WALTER;WEAVER, DONALD;AND OTHERS;REEL/FRAME:009950/0412;SIGNING DATES FROM 19950816 TO 19950823
|Dec 20, 2002||FPAY||Fee payment|
Year of fee payment: 4
|Jul 14, 2003||AS||Assignment|
Owner name: NEUROCHEM (INTERNATIONAL) LIMITED, GIBRALTAR
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROCHEM, INC.;REEL/FRAME:014250/0732
Effective date: 20030513
|Jul 12, 2006||FPAY||Fee payment|
Year of fee payment: 8
|Jul 31, 2008||AS||Assignment|
Owner name: BELLUS HEALTH (INTERNATIONAL) LIMITED, SWITZERLAND
Free format text: CHANGE OF NAME;ASSIGNOR:NEUROCHEM (INTERNATIONAL) LIMITED;REEL/FRAME:021373/0663
Effective date: 20080526
|Aug 16, 2010||REMI||Maintenance fee reminder mailed|
|Jan 12, 2011||LAPS||Lapse for failure to pay maintenance fees|
|Mar 1, 2011||FP||Expired due to failure to pay maintenance fee|
Effective date: 20110112